Intraperitoneal chemotherapy as first-line treatment in the management of epithelial ovarian cancer.
Recent evidence has suggested improved outcomes following incorporation of intraperitoneal chemotherapy administration with intravenous systemic chemotherapy as first-line treatment of small volume residual epithelial ovarian cancer. This review focuses on the mechanism of actions of the chemotherapeutic drugs and reviews the possible reasons for the superior outcomes of intraperitoneal chemotherapy.
Rekhraj
S
S
Department of Biosurgery and Surgical Technology, College London, 10th Floor QEQM Building, St Mary's Hospital, London W2 1NY, United Kingdom. sushil.rekhraj@imperial.ac.uk
Kinross
J
J
Prabhudesai
S
S
Darzi
A
A
Ziprin
P
P
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy*; D000075202:Contraindications; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents